ÖzetAmaç: Bu çal›flmada, klini¤imizde tedavi edilen larinks kanserli hastalar›n tedavi sonuçlar›, tedavilerin yan etkileri ve hastalar›n sa¤kal›-m›n› etkileyen prognostik faktörlerin belirlenmesi amaçlanm›flt›r.Yöntem: Çal›flmada 90 hasta verisi analiz edilmifltir. Hastalar›n performans statüsü 2010'da revize edilmifl Do¤u Onkoloji ‹flbirli¤i Grubu (Eastern Cooperative Oncology Group, ECOG) skorlama sistemine göre de¤erlendirilmifltir.
Bulgular:Hastalar›n %97'si erkek ve %3'ü kad›n olup, medyan yafl› 59 (37-86) idi. Erken evre %43, lokal ileri evre %55, metastatik evre kanser %2 hastada saptand›. Hastalar›n %53'ünü glottik kanserler, %47'sini supraglottik kanserler oluflturmaktayd›. Supraglottik kanserlerin performans durumu (p=0.022), grade (p=0.033), T evresi (p=0.034), lenf nod metastaz› (p=0.001), hastal›k evresi (p=0.007) bak›m›ndan glottik kanserlere göre daha kötü özelliklere sahip oldu¤u saptand›. Medyan 15 (da¤›l›m: 5-96) ayda hastalar›n %17'sinde nüks, medyan 17 (da¤›l›m: 1-155) ayda da hastalar›n %12'sinde uzak metastaz tespit edildi. Hastalar›n sa¤kal›m›n› komorbidite (p=0.032), performans durumu (p=0.022), hemoglobin düzeyi (p=0.003), T evresi (p=0.006), hastal›k evresi (p=0.011), kilo kayb› (p=0.002) etkilemekteydi. Kemoradyoterapi uygulanan hastalarda mukozit (p<0.001), bulant› kusma (p<0.001), kilo kayb› (p=0.005), nötropeni (p=0.001) ve anemi (p=0.003), radyoterapi uygulanan hastalara göre daha fazla gözlenmifltir.Sonuç: Hemoglobin düzeyi, T evresi, komorbidite ve kilo kayb› bu hastalar için ba¤›ms›z prognostik faktörler olmufltur.Anahtar sözcükler: Larinks kanseri, sa¤kal›m, prognoz, yan etki.
AbstractObjective: Our aim was to determine the treatment results, side effects and the prognostic factors affecting survival in patients with larynx cancer treated in our clinic.
Methods:Data of a total of 90 patients with larynx carcinoma were included in the study. The patients' performance scores were evaluated according to the Eastern Cooperative Oncology Group (ECOG) system.Results: Eighty-seven (97%) patients were male and three patients (3%) were female. The median age of the patients was 59 (37-86) years. Early-stage, locally advanced stage, and metastatic disease were detected in 43, 55, and 2% of the patients, respectively. Laryngeal cancers were observed in the glottic (53%), and supraglottic (47%) regions. Performance score (p=0.022), grade (p=0.033), lymph node metastasis (p=0.001), T stage (p=0.034) and disease stage (p=0.007) were significantly unfavourable in supraglottic cancers compared to glottic cancers. Recurrence was observed in 17% of the patients in a median 15 (range: 5-96) months. Distant metastasis was observed in 12% of the patients in a median 17 (range: 1-155) months. The factors affecting survival were the presence of comorbidities (p=0.032), performance status (p=0.022), hemoglobin level (p=0.003), T stage (p=0.006), disease stage (p=0.011), and weight loss (p=0.002). When RT-and CRT-associated side effects were compared, the incidence of adverse effects such as mucositis ...